Similar articles

• Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.

  Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC, et al. Zittoun R, et al. Leukemia. 1992;6 Suppl 2:76-7. Leukemia. 1992. PMID: 1578949 Clinical Trial. No abstract available.
• The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).

  Weinstein H, Ravindranath Y, Krischer J, Steuber P, Civin C, Gresik M, Vietti T. Weinstein H, et al. Leukemia. 1992;6 Suppl 2:52-4. Leukemia. 1992. PMID: 1578941 Clinical Trial. No abstract available.
• Remission induction therapy: the more intensive the better?

  Büchner T, Hiddemann W, Berdel W, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A. Büchner T, et al. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S41-4. doi: 10.1007/s002800100305. Cancer Chemother Pharmacol. 2001. PMID: 11587366
• New agents in the treatment of acute myeloid leukemia.

  Wiernik PH. Wiernik PH. Semin Hematol. 1991 Jul;28(3 Suppl 4):95-8. Semin Hematol. 1991. PMID: 1780763 Review. No abstract available.
• Optimal induction and post-remission therapy for AML in first remission.

  Rowe JM. Rowe JM. Hematology Am Soc Hematol Educ Program. 2009:396-405. doi: 10.1182/asheducation-2009.1.396. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008225 Review.